Physician participation in clinical studies and subsequent prescribing of new drugs

P and T

Volumn 30, Issue 1, 2005, Pages 60-66

  Corrigan, Mark H ^a   Glass, Harold E ^b,c,d  

^a SUNOVION PHARMACEUTICALS INC   (United States)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c UNIVERSITY OF THE SCIENCES   (United States)

^d TTC

Author keywords

Clinical trials; Pharmaceuticals; Prescribing

Indexed keywords

ARTHROTEC; BECLOMETASONE DIPROPIONATE; BUDESONIDE; CANDESARTAN HEXETIL; CELECOXIB; CERIVASTATIN; CYCLOSPORIN A; DALFOPRISTIN PLUS QUINUPRISTIN; ETODOLAC; FLESINOXAN; GLIMEPIRIDE; INSULIN ASPART; INSULIN LISPRO; IRBESARTAN; LANSOPRAZOLE; LEFLUNOMIDE; LEVOFLOXACIN; LORATADINE; MEROPENEM; MIBEFRADIL; MOMETASONE FUROATE; MONTELUKAST; MOXIFLOXACIN; NAPROXEN; NEW DRUG; OLANZAPINE; REPAGLINIDE; ROFECOXIB; SIBUTRAMINE; SINGULAIR S; SPARFLOXACIN; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN; VENLAFAXINE; ZAFIRLUKAST; ZILEUTON;

ARTICLE; CASE CONTROL STUDY; CLINICAL PRACTICE; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG DESIGN; HUMAN; PHYSICIAN; PRESCRIPTION; TREATMENT INDICATION; UNITED STATES;

EID: 13244268223     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Denig P, Haaijer-Ruskamp FM, Wesseling H, Versluis A. Impact of clinical trials on the adoption of new drugs within a university hospital. Eur J Clin Pharmacol 1991;41:325-328.
2. Jones MI, Greenfield SM, Jowett S, et al. Proton pump inhibitors: A study of GPs' prescribing. Fam Pract 2001;18:333-338.
3. Majumdar SR, Chang WC, Armstrong PW. Do the investigative sites that take part in a positive clinical trial translate that evidence into practice? Am J Med 2002;113:140-145.
4. Steffensen FH, Sorensen HT, Olesen F. Diffusion of new drugs in Danish general practice. Fam Pract 1999;16:407-413.
5. Anderson GF, Hurst J. Hussey PS, Jee-Hughes M. Health spending and outcomes: Trends in OECD [Organisation for Economic Co-operation and Development] Countries, 1960-1998. Health Aff 2000;19:150-157.
6. Tamblyn R, McLeod P, Hanley JA, et al. Physician and practice characteristics associated with the early utilization of new prescription drugs. Med Care 2003;41:895-908.
7. McKinney WP, Schiedermayer DL, Lurie N, et al. Attitudes of internal medicine faculty and residents towards professional interactions with pharmaceutical sales representatives. JAMA 1990;264:1693-1697.
8. Lichstein PR, Turner RC, O'Brien K. Impact of pharmaceutical company representatives on internal medicine residency programs: A survey of residency program directors. Arch Intern Med 1992;152;1009-1013.
9. Wazana A. Physicians and the pharmaceutical industry: Is a gift ever just a gift? JAMA 2000;283:373-380.
10. Omoigui NA, Silver MJ, Rybicki LA, et al. Influence of a randomized clinical trial on practice by participating investigators: Lessons from the coronary angioplasty versus excisional atherectomy trial (CAVEAT). J Am Coll Cardiol 1998;31:265-275.
11. Lexchin J. Interactions between physicians and the pharmaceutical industry: What does the literature say? Can Med Assoc J 1993;149:1401-1407.
12. Avorn J, Chen M, Hartley R. Scientific versus commercial sources of influence on the prescribing behavior of physicians. Am J Med 1982;73:4-8.
13. Guldal D, Semin S. The influences of drug companies' advertising programs on physicians. Int J Health Serv 2000;3:585-595.
14. Soumerai SB, McLaughlin TJ, Gurwitz JH, et al. Effect of local medical opinion leaders on quality of care for acute myocardial infarction: A randomized controlled trial. JAMA 1998;279: 1358-1363.
15. Soumerai SB, Majumdar SR, Lipton HL. Evaluating and improving physician prescribing. In: Strom B, ed. Pharmacoepidemiology, 3rd ed. Toronto, Canada: John Wiley & Sons; 2000:483-503.
16. Greer AL. The state of art versus the state of science: The diffusion of new medical technologies into practice. Int J Technol Assess Health Care 1988;4:5-26.
17. Naylor CD. Better care and better outcomes: The continuing challenge. JAMA 1998;279:1392-1394.
18. Rogers EM. Diffusion of Innovations, 4th ed. New York: The Free Press; 1995;189-203.
19. Peay MY, Peay ER. The role of commercial sources in the adoption of a new drug. Soc Sci Med 1988;26:1183-1189.
20. Miller RR. Prescribing habits of physicians: A review of studies on prescribing of drugs (Parts I-III). Drug Intelligence Clin Pharmacy 1973;7:492-500.
21. PICAS® [database]. Fort Washington, PA: Data Edge, LLC; 1992. (No longer commercially available; rights sold to IMS Health in 2002.)
22. Glass HE, Sullivan JM. Managing clinical grant costs through the use of unaffiliated investigators. Drug Information J 1995;29.
23. R&D Insight [database online]. Yardley, PA: Wolters Kluwer Health, Pharma Solutions Division; 1995. Updated daily.
24. Xponent® [database]. Plymouth Meeting, PA: IMS Health, Inc.; 1975. Updated daily.
25. Hovde M, Seskin R. Selecting U.S. clinical investigators. Appl Clin Trials 1997;6:34-42.
26. Glass HE, Kane RA. Higher payments to investigators don't speed study completion. Appl Clin Trials 1995;9:46-54.